Livalo pitavastatin regulatory update

FDA approved an NDA from Kowa for Livalo pitavastatin to treat primary hypercholesterolemia and combined dyslipidemia. Kowa expects to launch the HMG-CoA reductase inhibitor in the U.S. in 1Q10. Lival...